Key Points
- ANI Pharmaceuticals VP Meredith Cook sold 500 shares on July 13 at an average price of $81.84, totaling $40,920, in a transaction made under a pre-arranged Rule 10b5-1 plan.
- Cook has sold shares repeatedly in recent months, including 500 shares on June 12 and 500 shares on May 13, indicating a pattern of modest insider selling.
- The company reported strong recent results, with quarterly EPS of $2.05 beating estimates and revenue rising 20.5% year over year; analysts currently rate the stock a Moderate Buy with a $107.33 average target price.
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) VP Meredith Cook sold 500 shares of ANI Pharmaceuticals stock in a transaction that occurred on Monday, July 13th. The stock was sold at an average price of $81.84, for a total transaction of $40,920.00. Following the completion of the sale, the vice president owned 77,390 shares of the company's stock, valued at $6,333,597.60. This represents a 0.64% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Meredith Cook also recently made the following trade(s):
- On Friday, June 12th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $82.03, for a total transaction of $41,015.00.
- On Wednesday, May 13th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $78.16, for a total transaction of $39,080.00.
ANI Pharmaceuticals Price Performance
Shares of ANIP opened at $80.55 on Wednesday. The firm has a fifty day simple moving average of $81.53 and a two-hundred day simple moving average of $79.51. The firm has a market cap of $1.83 billion, a PE ratio of 20.39 and a beta of 0.43. The company has a current ratio of 3.12, a quick ratio of 2.52 and a debt-to-equity ratio of 1.06. ANI Pharmaceuticals, Inc. has a 1-year low of $62.60 and a 1-year high of $99.50.
ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last issued its quarterly earnings data on Friday, May 8th. The specialty pharmaceutical company reported $2.05 EPS for the quarter, topping the consensus estimate of $1.28 by $0.77. The company had revenue of $237.46 million during the quarter, compared to analyst estimates of $207.63 million. ANI Pharmaceuticals had a return on equity of 27.51% and a net margin of 9.98%.ANI Pharmaceuticals's revenue was up 20.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.70 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, equities analysts anticipate that ANI Pharmaceuticals, Inc. will post 8.03 EPS for the current year.
Institutional Investors Weigh In On ANI Pharmaceuticals
A number of institutional investors have recently bought and sold shares of ANIP. KBC Group NV purchased a new position in shares of ANI Pharmaceuticals in the first quarter valued at about $28,000. Advisors Asset Management Inc. purchased a new stake in shares of ANI Pharmaceuticals during the first quarter worth about $28,000. Hantz Financial Services Inc. grew its position in shares of ANI Pharmaceuticals by 70.3% during the fourth quarter. Hantz Financial Services Inc. now owns 603 shares of the specialty pharmaceutical company's stock worth $48,000 after purchasing an additional 249 shares in the last quarter. Kemnay Advisory Services Inc. bought a new stake in ANI Pharmaceuticals during the 4th quarter valued at approximately $48,000. Finally, State of Wyoming bought a new stake in ANI Pharmaceuticals during the 2nd quarter valued at approximately $50,000. Hedge funds and other institutional investors own 76.05% of the company's stock.
Wall Street Analysts Forecast Growth
Several research firms have recently commented on ANIP. Zacks Research lowered shares of ANI Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 14th. Guggenheim reissued a "buy" rating and issued a $124.00 price objective on shares of ANI Pharmaceuticals in a report on Friday, July 10th. Weiss Ratings upgraded shares of ANI Pharmaceuticals from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Tuesday, June 23rd. Finally, Wall Street Zen raised shares of ANI Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Saturday, May 9th. Six investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $107.33.
View Our Latest Stock Report on ANI Pharmaceuticals
ANI Pharmaceuticals Company Profile
(
Get Free Report)
ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.
ANI's product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
